| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6843
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2010-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3df7e96d67b3ecb69740320e990507e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99d9b7a3b1761f321698ab6a59b52791
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f35143cd76b4e965f9f00067d52763e4 |
| publicationDate |
2012-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120092611-A |
| titleOfInvention |
Drug Fusions and Conjugates with Extended Half-Life |
| abstract |
The present invention relates to drug fusions and conjugates with improved serum half-life. Such fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulin secretagogue and / or incretin and / or gut peptide molecules. The invention also relates to the use of the drug fusions and conjugates, as well as to agents, compositions and devices comprising the same. The invention also relates to a composition comprising one or more insulin secretagogue and / or incretin and / or gut peptide molecules present as part of the fusion or conjugate, and uses and formulations thereof. |
| priorityDate |
2009-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |